195 related articles for article (PubMed ID: 15949430)
1. [Clinical analysis of 91 cases of hereditary breast and ovarian cancer].
Li N; Wu LY; Zhang R; Zhang X; Liu LY
Zhonghua Zhong Liu Za Zhi; 2005 Apr; 27(4):245-7. PubMed ID: 15949430
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathological characteristics of hereditary ovarian cancer syndrome].
Zhong Y; Sheng XG; Ma ZF; Ma YB; Liu NF; Chen YT; Gao R; Wang YY; Sun L
Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):676-80. PubMed ID: 20079180
[TBL] [Abstract][Full Text] [Related]
3. Hereditary breast/ovarian cancer: clinicopathological characteristics and survival of BRCA2 positive and negative cases.
Syamala V; Syamala VS; Sreeja L; Raveendran PB; Vijayalekshmi RV; Sheeja VR; Santhi S; Kuttan R; Abraham EK; Ankathil R
J Exp Ther Oncol; 2008; 7(3):227-36. PubMed ID: 19066131
[TBL] [Abstract][Full Text] [Related]
4. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
5. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
6. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
[TBL] [Abstract][Full Text] [Related]
7. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
9. [The clinical and pathological characteristics of epithelial ovarian carcinoma in patients with age under 40].
Wen H; Sun W; Guo Y
Zhonghua Fu Chan Ke Za Zhi; 1997 Sep; 32(9):548-51. PubMed ID: 9639757
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of familial aggregation of ovarian and breast cancer in patients with ovarian cancer].
Ichikawa Y; Nishida M; Sugita M; Arisawa Y; Satoh T; Oki A; Kohno K; Shigemitsu S; Tsunoda H; Kubo T
Nihon Sanka Fujinka Gakkai Zasshi; 1995 Sep; 47(9):901-6. PubMed ID: 7594899
[TBL] [Abstract][Full Text] [Related]
11. [Construction and utilization of the prognostic model of serous ovarian adenocarcinoma].
Yang R; Feng J; Fang XZ; Bai F; Cheng YX; Liu C; Zhu W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2006 Jul; 41(7):459-63. PubMed ID: 17083811
[TBL] [Abstract][Full Text] [Related]
12. Patients with a history of epithelial ovarian cancer presenting with a breast and/or axillary mass.
Karam AK; Stempel M; Barakat RR; Morrow M; Gemignani ML
Gynecol Oncol; 2009 Mar; 112(3):490-5. PubMed ID: 19101713
[TBL] [Abstract][Full Text] [Related]
13. Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?
Vineyard MA; Daniels MS; Urbauer DL; Deavers MT; Sun CC; Boerwinkle E; Bodurka DC; Gershenson DM; Crawford J; Lu KH
Gynecol Oncol; 2011 Feb; 120(2):229-32. PubMed ID: 21126756
[TBL] [Abstract][Full Text] [Related]
14. Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.
Storey DJ; Rush R; Stewart M; Rye T; Al-Nafussi A; Williams AR; Smyth JF; Gabra H
Cancer; 2008 May; 112(10):2211-20. PubMed ID: 18344211
[TBL] [Abstract][Full Text] [Related]
15. Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study.
Figueiredo JC; Ennis M; Knight JA; McLaughlin JR; Hood N; O'Malley F; Andrulis IL; Goodwin PJ
Breast Cancer Res Treat; 2007 Sep; 105(1):69-80. PubMed ID: 17115108
[TBL] [Abstract][Full Text] [Related]
16. [Diagnosis and management strategies of hereditary ovarian cancer syndrome].
Shen K; Lang J; Huang R
Zhonghua Fu Chan Ke Za Zhi; 1996 Dec; 31(12):732-5. PubMed ID: 9387515
[TBL] [Abstract][Full Text] [Related]
17. Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer.
Takao M; Okamoto A; Nikaido T; Urashima M; Takakura S; Saito M; Saito M; Okamoto S; Takikawa O; Sasaki H; Yasuda M; Ochiai K; Tanaka T
Oncol Rep; 2007 Jun; 17(6):1333-9. PubMed ID: 17487387
[TBL] [Abstract][Full Text] [Related]
18. Hereditary ovarian cancer.
Prat J; Ribé A; Gallardo A
Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
[TBL] [Abstract][Full Text] [Related]
19. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma.
Liu JF; Hirsch MS; Lee H; Matulonis UA
Gynecol Oncol; 2009 Dec; 115(3):401-6. PubMed ID: 19796795
[TBL] [Abstract][Full Text] [Related]
20. Relapse and survival in early-stage ovarian cancer.
Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
